{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:22:39Z","timestamp":1790720559471,"version":"4.1.0"},"reference-count":98,"publisher":"Pacini Editore","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Otorhinolaryngol Ital"],"DOI":"10.14639\/0392-100x-n2223","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T10:38:50Z","timestamp":1684233530000},"page":"155-169","source":"Crossref","is-referenced-by-count":19,"title":["Nasopharyngeal carcinoma. A \u201cdifferent\u201d head and neck tumour. Part B: treatment, prognostic factors, and outcomes","Carcinoma rinofaringeo. Un tumore della testa e collo \u201cdiverso\u201d. Parte B: trattamento, fattori prognostici e risultati a distanza"],"prefix":"10.14639","volume":"43","author":[{"given":"Giulio","family":"Cant\u00f9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"20340","published-online":{"date-parts":[[2023,6]]},"reference":[{"key":"10.14639\/0392-100X-N2223_ref1","doi-asserted-by":"crossref","unstructured":"Sun XS, Li XY, Chen QY, et al. Future of radiotherapy in nasopharyngeal carcinoma. Br J Radiol 2019;92:20190209. https:\/\/doi.org\/10.1259\/bjr.20190209","DOI":"10.1259\/bjr.20190209"},{"key":"10.14639\/0392-100X-N2223_ref2","doi-asserted-by":"crossref","unstructured":"Cellai E, Chiavacci A, Olmi P, et al. Carcinoma of the nasopharynx: results of radiation therapy. Acta Radiol Oncol 1982;21:87-95. https:\/\/doi.org\/10.3109\/02841868209133989","DOI":"10.3109\/02841868209133989"},{"key":"10.14639\/0392-100X-N2223_ref3","unstructured":"Lee AW, Foo W, Law SC, et al. Nasopharyngeal carcinoma: presenting symptoms and duration before diagnosis. Hong Kong Med J 1997;3:355-361."},{"key":"10.14639\/0392-100X-N2223_ref4","doi-asserted-by":"crossref","unstructured":"Du T, Xiao J, Qiu Z, et al. Wu K. The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis. PLoS One 2019;14:E0219611. https:\/\/doi.org\/10.1371\/journal.pone.0219611","DOI":"10.1371\/journal.pone.0219611"},{"key":"10.14639\/0392-100X-N2223_ref5","doi-asserted-by":"crossref","unstructured":"Kong FF, Ying H, Du CR, et al. Effectiveness and toxicities of intensity-modulated radiation therapy for patients with T4 nasopharyngeal carcinoma. PLoS One 2014;9:E91362. https:\/\/doi.org\/10.1371\/journal.pone.0091362","DOI":"10.1371\/journal.pone.0091362"},{"key":"10.14639\/0392-100X-N2223_ref6","doi-asserted-by":"crossref","unstructured":"Huang TL, Chien CY, Tsai WL, et al. Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy. Head Neck 2016;38 (Suppl 1):E1026-E1032. https:\/\/doi.org\/10.1002\/hed.24150","DOI":"10.1002\/hed.24150"},{"key":"10.14639\/0392-100X-N2223_ref7","doi-asserted-by":"crossref","unstructured":"Weng JJ, Wei JZ, Li M, et al. Prognostic value of hypothyroidism in patients undergoing intensity-modulated radiation therapy for nasopharyngeal carcinoma. Head Neck 2022;44:1114-1123. https:\/\/doi.org\/10.1002\/hed.27006","DOI":"10.1002\/hed.27006"},{"key":"10.14639\/0392-100X-N2223_ref8","doi-asserted-by":"crossref","unstructured":"Bossi P, Chan AT, Licitra L, et al. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32:452-465. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.007","DOI":"10.1016\/j.annonc.2020.12.007"},{"key":"10.14639\/0392-100X-N2223_ref9","doi-asserted-by":"crossref","unstructured":"Li G, Xia YF, Huang YX, et al. Intensity-modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: cost-effectiveness analysis. Head Neck 2022;44:431-442. https:\/\/doi.org\/10.1002\/hed.26941","DOI":"10.1002\/hed.26941"},{"key":"10.14639\/0392-100X-N2223_ref10","doi-asserted-by":"crossref","unstructured":"Moreno AC, Frank SJ, Garden AS, et al. Intensity modulated proton therapy (IMPT) \u2013 the future of IMRT for head and neck cancer. Oral Oncol 2019;88:66-74. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.11.015","DOI":"10.1016\/j.oraloncology.2018.11.015"},{"key":"10.14639\/0392-100X-N2223_ref11","doi-asserted-by":"crossref","unstructured":"Taheri-Kadkhoda Z, Bj\u00f6rk-Eriksson T, et al. Intensity-modulated radiotherapy of nasopharyngeal carcinoma: a comparative treatment planning study of photons and protons. Radiat Oncol 2008;3:4. https:\/\/doi.org\/10.1186\/1748-717X-3-4","DOI":"10.1186\/1748-717X-3-4"},{"key":"10.14639\/0392-100X-N2223_ref12","doi-asserted-by":"crossref","unstructured":"Lewis GD, Holliday EB, Kocak-Uzel E, et al. Intensity-modulated proton therapy for nasopharyngeal carcinoma: Decreased radiation dose to normal structures and encouraging clinical outcomes. Head Neck 2016;38 (Suppl 1):E1886-E1895. https:\/\/doi.org\/10.1002\/hed.24341","DOI":"10.1002\/hed.24341"},{"key":"10.14639\/0392-100X-N2223_ref13","doi-asserted-by":"crossref","unstructured":"Rossi A, Molinari R, Boracchi P, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 1988;6:1401-1410. https:\/\/doi.org\/10.1200\/JCO.1988.6.9.1401","DOI":"10.1200\/JCO.1988.6.9.1401"},{"key":"10.14639\/0392-100X-N2223_ref14","doi-asserted-by":"crossref","unstructured":"Palazzi M, Guzzo M, Bossi P, et al. Regionally advanced nasopharyngeal carcinoma: long-term outcome after sequential chemotherapy and radiotherapy. Tumori 2004;90:60-65.","DOI":"10.1177\/030089160409000114"},{"key":"10.14639\/0392-100X-N2223_ref15","doi-asserted-by":"crossref","unstructured":"Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317. https:\/\/doi.org\/10.1200\/JCO.1998.16.4.1310","DOI":"10.1200\/JCO.1998.16.4.1310"},{"key":"10.14639\/0392-100X-N2223_ref16","doi-asserted-by":"crossref","unstructured":"Kim TH, McLaren J, Alvarado CS, et al. Adjuvant chemotherapy for advanced nasopharyngeal carcinoma in childhood. Cancer 1989;63:1922-1926. https:\/\/doi.org\/10.1002\/1097-0142(19890515)63:10<1922::aid-cncr2820631009>3.0.co;2-r","DOI":"10.1002\/1097-0142(19890515)63:10<1922::AID-CNCR2820631009>3.0.CO;2-R"},{"key":"10.14639\/0392-100X-N2223_ref17","doi-asserted-by":"crossref","unstructured":"Roper HP, Essex-Cater A, Marsden HB, et al. Nasopharyngeal carcinoma in children. Pediatr Hematol Oncol 1986;3:143-152. 1 https:\/\/doi.org\/0.3109\/08880018609031210","DOI":"10.3109\/08880018609031210"},{"key":"10.14639\/0392-100X-N2223_ref18","doi-asserted-by":"crossref","unstructured":"Chen QY, Wen YF, Guo L, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst 2011;103:1761-1770. https:\/\/doi.org\/10.1093\/jnci\/djr432","DOI":"10.1093\/jnci\/djr432"},{"key":"10.14639\/0392-100X-N2223_ref19","doi-asserted-by":"crossref","unstructured":"Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 2002;25:219-223. https:\/\/doi.org\/10.1097\/00000421-200206000-00002","DOI":"10.1097\/00000421-200206000-00002"},{"key":"10.14639\/0392-100X-N2223_ref20","unstructured":"National Comprehensive Cancer Network. Head and neck cancers (Version 3.2021). http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bone.pdf"},{"key":"10.14639\/0392-100X-N2223_ref21","doi-asserted-by":"crossref","unstructured":"Xu C, Zhang LH, Chen YP, et al. Chemoradiotherapy versus radiotherapy alone in stage ii nasopharyngeal carcinoma: a systemic review and meta-analysis of 2138 patients. J Cancer 2017;8:287-297. https:\/\/doi.org\/10.7150\/jca.17317","DOI":"10.7150\/jca.17317"},{"key":"10.14639\/0392-100X-N2223_ref22","doi-asserted-by":"crossref","unstructured":"Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012;13:163-171. https:\/\/doi.org\/10.1016\/S1470-2045(11)70320-5.","DOI":"10.1016\/S1470-2045(11)70320-5"},{"key":"10.14639\/0392-100X-N2223_ref23","doi-asserted-by":"crossref","unstructured":"Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 2019;381:1124-1135. https:\/\/doi.org\/10.1056\/NEJMoa1905287","DOI":"10.1056\/NEJMoa1905287"},{"key":"10.14639\/0392-100X-N2223_ref24","doi-asserted-by":"crossref","unstructured":"Liu T, Dai S, Zhang H, Zhong X, et al. The best choice of induction chemotherapy for patients with locally advanced nasopharyngeal carcinoma: Bayesian network meta-analysis. Head Neck 2022;44:518-529. https:\/\/doi.org\/10.1002\/hed.26932","DOI":"10.1002\/hed.26932"},{"key":"10.14639\/0392-100X-N2223_ref25","doi-asserted-by":"crossref","unstructured":"Li WZ, Lv X, Hu D, et al. Effect of induction chemotherapy with paclitaxel, cisplatin, and capecitabine vs cisplatin and fluorouracil on failure-free survival for patients with stage IVA to IVB nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol 2022;8:706-714. https:\/\/doi.org\/10.1001\/jamaoncol.2022.0122","DOI":"10.1001\/jamaoncol.2022.0122"},{"key":"10.14639\/0392-100X-N2223_ref26","doi-asserted-by":"crossref","unstructured":"Li M, Zhang B, Chen Q, et al. Concurrent chemoradiotherapy with additional chemotherapy for nasopharyngeal carcinoma: a pooled analysis of propensity score-matching studies. Head Neck 2021;43:1912-1927. https:\/\/doi.org\/10.1002\/hed.26664","DOI":"10.1002\/hed.26664"},{"key":"10.14639\/0392-100X-N2223_ref27","doi-asserted-by":"crossref","unstructured":"Zhao C, Miao JJ, Hua YJ, et al. Locoregional control and mild late toxicity after reducing target volumes and radiation doses in patients with locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy (ic) followed by concurrent chemoradiotherapy: 10-year results of a phase 2 study. Int J Radiat Oncol Biol Phys 2019;104:836-844. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.03.043","DOI":"10.1016\/j.ijrobp.2019.03.043"},{"key":"10.14639\/0392-100X-N2223_ref28","doi-asserted-by":"crossref","unstructured":"Jiang YT, Chen KH, Liang ZG, et al. A nomogram based on tumor response to induction chemotherapy may predict survival in locoregionally advanced nasopharyngeal carcinoma. Head Neck 2022;44:1301-1312. https:\/\/doi.org\/10.1002\/hed.27020","DOI":"10.1002\/hed.27020"},{"key":"10.14639\/0392-100X-N2223_ref29","doi-asserted-by":"crossref","unstructured":"Jiang YT, Chen KH, Yang J, et al. Prognostic significance of wait time for radical radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Head Neck 2022;44:1182-1191. https:\/\/doi.org\/10.1002\/hed.27011","DOI":"10.1002\/hed.27011"},{"key":"10.14639\/0392-100X-N2223_ref30","doi-asserted-by":"crossref","unstructured":"He Y, Zhao Z, Wang Y, et al. Optimizing number of cycles of induction chemotherapy for patients with nasopharyngeal carcinoma: retrospective survival analysis. Head Neck 2020;42:2067-2076. https:\/\/doi.org\/10.1002\/hed.26141","DOI":"10.1002\/hed.26141"},{"key":"10.14639\/0392-100X-N2223_ref31","doi-asserted-by":"crossref","unstructured":"Ribassin-Majed L, Marguet S, Lee AWM, et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol 2017;35:498-505. https:\/\/doi.org\/10.1200\/JCO.2016.67.4119","DOI":"10.1200\/JCO.2016.67.4119"},{"key":"10.14639\/0392-100X-N2223_ref32","doi-asserted-by":"crossref","unstructured":"Tang L, Mao Y, Liu L, et al. The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging. Cancer 2009;115:680-688. https:\/\/doi.org\/10.1002\/cncr.24049","DOI":"10.1002\/cncr.24049"},{"key":"10.14639\/0392-100X-N2223_ref33","doi-asserted-by":"crossref","unstructured":"Liu YP, Lv X, Zou X, et al. Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma. Cancer Commun (Lond). 2019;39:75. https:\/\/doi.org\/\/10.1186\/s40880-019-0415-3","DOI":"10.1186\/s40880-019-0415-3"},{"key":"10.14639\/0392-100X-N2223_ref34","doi-asserted-by":"crossref","unstructured":"Zhang B, Li Y, Weng J, et al. Efficacy and safety of endoscopic nasopharyngectomy combined with low-dose radiotherapy for primary T1-2 nasopharyngeal carcinoma. Technol Cancer Res Treat 2021;20:15330338211011975. https:\/\/doi.org\/10.1177\/15330338211011975","DOI":"10.1177\/15330338211011975"},{"key":"10.14639\/0392-100X-N2223_ref35","doi-asserted-by":"crossref","unstructured":"Bashraheel SS, Domling A, Goda SK. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. Biomed Pharmacother 2020;125:110009. https:\/\/doi.org\/10.1016\/j.biopha.2020.110009","DOI":"10.1016\/j.biopha.2020.110009"},{"key":"10.14639\/0392-100X-N2223_ref36","doi-asserted-by":"crossref","unstructured":"Kang Y, He W, Ren C, et al. Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma. Signal Transduct Target Ther 2020;5:245. https:\/\/doi.org\/10.1038\/s41392-020-00340-2","DOI":"10.1038\/s41392-020-00340-2"},{"key":"10.14639\/0392-100X-N2223_ref37","doi-asserted-by":"crossref","unstructured":"Kong F, Ying H, Du C, et al. Patterns of local-regional failure after primary intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiat Oncol 2014;9:60. https:\/\/doi.org\/0.1186\/1748-717X-9-60","DOI":"10.1186\/1748-717X-9-60"},{"key":"10.14639\/0392-100X-N2223_ref38","doi-asserted-by":"crossref","unstructured":"Liu X, Wu B, Huang J, et al. Tumor factors associated with in-field failure for nasopharyngeal carcinoma after intensity-modulated radiotherapy. Head Neck 2022;44:876-888. https:\/\/doi.org\/10.1002\/hed.26983","DOI":"10.1002\/hed.26983"},{"key":"10.14639\/0392-100X-N2223_ref39","doi-asserted-by":"crossref","unstructured":"Zhang W, Li L, Guo E, et al. Inhibition of PDK1 enhances radiosensitivity and reverses epithelial-mesenchymal transition in nasopharyngeal carcinoma. Head Neck 2022;44:1576-1587. https:\/\/doi.org\/10.1002\/hed.27053","DOI":"10.1002\/hed.27053"},{"key":"10.14639\/0392-100X-N2223_ref40","doi-asserted-by":"crossref","unstructured":"Wessberg GA, Hill SC, McBride KL. Median labiomandibular glossotomy. Int J Oral Surg 1981;10:333-337. https:\/\/doi.org\/10.1016\/s0300-9785(81)80030-0","DOI":"10.1016\/S0300-9785(81)80030-0"},{"key":"10.14639\/0392-100X-N2223_ref41","doi-asserted-by":"crossref","unstructured":"Fisch U. The infratemporal fossa approach for nasopharyngeal tumors. Laryngoscope 1983;93:36-44. https:\/\/doi.org\/10.1288\/00005537-198301000-00007","DOI":"10.1288\/00005537-198301000-00007"},{"key":"10.14639\/0392-100X-N2223_ref42","doi-asserted-by":"crossref","unstructured":"Janecka IP, Sen CN, Sekhar LN, et al. Facial translocation for cranial base surgery. Keio J Med 1991;40:215-220. https:\/\/doi.org\/10.2302\/kjm.40.215","DOI":"10.2302\/kjm.40.215"},{"key":"10.14639\/0392-100X-N2223_ref43","doi-asserted-by":"crossref","unstructured":"Wei WI, Lam KH, Sham JS. New approach to the nasopharynx: the maxillary swing approach. Head Neck 1991;13:200-207. https:\/\/doi.org\/10.1002\/hed.2880130306","DOI":"10.1002\/hed.2880130306"},{"key":"10.14639\/0392-100X-N2223_ref44","doi-asserted-by":"crossref","unstructured":"Chan JY, Tsang RK, Wei WI. Morbidities after maxillary swing nasopharyngectomy for recurrent nasopharyngeal carcinoma. Head Neck 2015;37:487-492. https:\/\/doi.org\/10.1002\/hed.23633","DOI":"10.1002\/hed.23633"},{"key":"10.14639\/0392-100X-N2223_ref45","doi-asserted-by":"crossref","unstructured":"Yoshizaki T, Wakisaka N, Murono S, et al. Endoscopic nasopharyngectomy for patients with recurrent nasopharyngeal carcinoma at the primary site. Laryngoscope 2005;115:1517-1519.","DOI":"10.1097\/01.MLG.0000165383.35100.17"},{"key":"10.14639\/0392-100X-N2223_ref46","doi-asserted-by":"crossref","unstructured":"Yang J, Song X, Sun X, et al. Outcomes of recurrent nasopharyngeal carcinoma patients treated with endoscopic nasopharyngectomy: a meta-analysis. Int Forum Allergy Rhinol 2020;10:1001-1011. https:\/\/doi.org\/10.1002\/alr.22552","DOI":"10.1002\/alr.22552"},{"key":"10.14639\/0392-100X-N2223_ref47","doi-asserted-by":"crossref","unstructured":"Liu YP, Wen YH, Tang J, et al. Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021;22:381-390. https:\/\/doi.org\/10.1016\/S1470-2045(20)30673-2","DOI":"10.1016\/S1470-2045(20)30673-2"},{"key":"10.14639\/0392-100X-N2223_ref48","doi-asserted-by":"crossref","unstructured":"Ozer E, Waltonen J. Transoral robotic nasopharyngectomy: a novel approach for nasopharyngeal lesions. Laryngoscope 2008;118:1613-1616. https:\/\/doi.org\/10.1097\/MLG.0b013e3181792490","DOI":"10.1097\/MLG.0b013e3181792490"},{"key":"10.14639\/0392-100X-N2223_ref49","doi-asserted-by":"crossref","unstructured":"Tsang RK, To VS, Ho AC, et al. Early results of robotic assisted nasopharyngectomy for recurrent nasopharyngeal carcinoma. Head Neck 2015;37:788-793. https:\/\/doi.org\/10.1002\/hed.23672","DOI":"10.1002\/hed.23672"},{"key":"10.14639\/0392-100X-N2223_ref50","doi-asserted-by":"crossref","unstructured":"Tsang RK, Holsinger FC. Transoral endoscopic nasopharyngectomy with a flexible next-generation robotic surgical system. Laryngoscope 2016;126:2257-2262. https:\/\/doi.org\/10.1002\/lary.25970","DOI":"10.1002\/lary.25970"},{"key":"10.14639\/0392-100X-N2223_ref51","doi-asserted-by":"crossref","unstructured":"Tsang RK, Chan WCP, Holsinger FC, et al. Long-term results of robotic-assisted nasopharyngectomy for recurrent nasopharyngeal carcinoma. Head Neck 2022;44:1940-1947. https:\/\/doi.org\/10.1002\/hed.27115","DOI":"10.1002\/hed.27115"},{"key":"10.14639\/0392-100X-N2223_ref52","doi-asserted-by":"crossref","unstructured":"Li JG, Venigalla P, Leeman JE, et al. Patterns of nodal failure after intensity modulated radiotherapy for nasopharyngeal carcinoma. Laryngoscope 2017;127:377-382. https:\/\/doi.org\/10.1002\/lary.26139","DOI":"10.1002\/lary.26139"},{"key":"10.14639\/0392-100X-N2223_ref53","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhu YX, Wang Y, et al. Salvage surgery for neck residue or recurrence of nasopharyngeal carcinoma: a 10-year experience. Ann Surg Oncol 2011;18:233-238. https:\/\/doi.org\/10.1245\/s10434-010-1292-9","DOI":"10.1245\/s10434-010-1292-9"},{"key":"10.14639\/0392-100X-N2223_ref54","doi-asserted-by":"crossref","unstructured":"Wei WI, Ho CM, Wong MP, et al. Pathological basis of surgery in the management of postradiotherapy cervical metastasis in nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 1992;118:923-929; discussion 930. https:\/\/doi.org\/10.1001\/archotol.1992.01880090039012","DOI":"10.1001\/archotol.1992.01880090039012"},{"key":"10.14639\/0392-100X-N2223_ref55","doi-asserted-by":"crossref","unstructured":"Yen KL, Hsu LP, Sheen TS, et al. Salvage neck dissection for cervical recurrence of nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 1997;123:725-729. https:\/\/doi.org\/0.1001\/archotol.1997.01900070069011","DOI":"10.1001\/archotol.1997.01900070069011"},{"key":"10.14639\/0392-100X-N2223_ref56","doi-asserted-by":"crossref","unstructured":"Wang SY, Lou JL, Chen J, et al. Salvage surgery for neck residue or recurrence of nasopharyngeal carcinoma after primary radiotherapy: options of surgical methods and regions. World J Surg Oncol 2016;14:89. https:\/\/doi.org\/10.1186\/s12957-016-0822-8","DOI":"10.1186\/s12957-016-0822-8"},{"key":"10.14639\/0392-100X-N2223_ref57","doi-asserted-by":"crossref","unstructured":"Khor TH, Tan BC, Chua EJ, et al. Distant metastases in nasopharyngeal carcinoma. Clin Radiol 1978;29:27-30. https:\/\/doi.org\/10.1016\/s0009-9260(78)80160-3","DOI":"10.1016\/S0009-9260(78)80160-3"},{"key":"10.14639\/0392-100X-N2223_ref58","doi-asserted-by":"crossref","unstructured":"Ai QY, Hu CW, Bhatia KS, et al. Nasopharyngeal carcinoma: relationship between invasion of the prevertebral space and distant metastases. Eur Arch Otorhinolaryngol 2018;275:497-505. https:\/\/doi.org\/10.1007\/s00405-017-4825-z","DOI":"10.1007\/s00405-017-4825-z"},{"key":"10.14639\/0392-100X-N2223_ref59","doi-asserted-by":"crossref","unstructured":"Liu GY, Li WZ, Wang DS, et al. Effect of capecitabine maintenance therapy plus best supportive care vs best supportive care alone on progression-free survival among patients with newly diagnosed metastatic nasopharyngeal carcinoma who had received induction chemotherapy: a phase 3 randomized clinical trial. JAMA Oncol 2022;8:553-561. https:\/\/doi.org\/10.1001\/jamaoncol.2021.7366","DOI":"10.1001\/jamaoncol.2021.7366"},{"key":"10.14639\/0392-100X-N2223_ref60","doi-asserted-by":"crossref","unstructured":"Xu H, Lu L, Lu T, et al. Identifying the optimal candidates for locoregional radiation therapy in patients with de novo metastatic nasopharyngeal carcinoma. Head Neck 2021;43:2602-2610. https:\/\/doi.org\/10.1002\/hed.26726","DOI":"10.1002\/hed.26726"},{"key":"10.14639\/0392-100X-N2223_ref61","doi-asserted-by":"crossref","unstructured":"Yang L, Xue Y, Wei Z, et al. Local radiotherapy versus nonradiotherapy to distant lesions for metastatic nasopharyngeal carcinoma: retrospective cohort study. Head Neck 2022;44:615-623. https:\/\/doi.org\/10.1002\/hed.26953","DOI":"10.1002\/hed.26953"},{"key":"10.14639\/0392-100X-N2223_ref62","doi-asserted-by":"crossref","unstructured":"Qu W, Li S, Zhang M, et al. Pattern and prognosis of distant metastases in nasopharyngeal carcinoma: a large-population retrospective analysis. Cancer Med 2020;9:6147-6158. https:\/\/doi.org\/10.1002\/cam4.3301","DOI":"10.1002\/cam4.3301"},{"key":"10.14639\/0392-100X-N2223_ref63","doi-asserted-by":"crossref","unstructured":"Yang ZC, Luo MJ, Sun XS, et al. Definitive radiation therapy and liver local therapy in de novo liver metastatic nasopharyngeal carcinoma: large cohort study. Head Neck 2022;44:1057-1068. https:\/\/doi.org\/10.1002\/hed.26999","DOI":"10.1002\/hed.26999"},{"key":"10.14639\/0392-100X-N2223_ref64","doi-asserted-by":"crossref","unstructured":"Xu JY, Wei XL, Wang YQ, et al. Current status and advances of immunotherapy in nasopharyngeal carcinoma. Ther Adv Med Oncol 2022;14:17588359221096214. https:\/\/doi.org\/10.1177\/17588359221096214","DOI":"10.1177\/17588359221096214"},{"key":"10.14639\/0392-100X-N2223_ref65","unstructured":"Barnes L, Eveson JW, Reichart P, et al., eds. World Health Organization Classification of Tumours. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC Press; 2005."},{"key":"10.14639\/0392-100X-N2223_ref66","doi-asserted-by":"crossref","unstructured":"Haghbin M, Kramer S, Patchefsky AS, et al. Carcinoma of the nasopharynx. A 25-year study. Am J Clin Oncol 1985;8:384-392. https:\/\/doi.org\/10.1097\/00000421-198510000-00009","DOI":"10.1097\/00000421-198510000-00009"},{"key":"10.14639\/0392-100X-N2223_ref67","doi-asserted-by":"crossref","unstructured":"Vikram B, Strong EW, Manolatos S, et al. Improved survival in carcinoma of the nasopharynx. Head Neck Surg 1984;7:123-128. https:\/\/doi.org\/10.1002\/hed.2890070206","DOI":"10.1002\/hed.2890070206"},{"key":"10.14639\/0392-100X-N2223_ref68","doi-asserted-by":"crossref","unstructured":"Yeh SA, Hwang TZ, Wang CC, et al. Outcomes of patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. J Radiat Res 2021;62:438-447. https:\/\/doi.org\/10.1093\/jrr\/rrab008","DOI":"10.1093\/jrr\/rrab008"},{"key":"10.14639\/0392-100X-N2223_ref69","doi-asserted-by":"crossref","unstructured":"Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 2005;61:1107-1116. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.07","DOI":"10.1016\/j.ijrobp.2004.07.702"},{"key":"10.14639\/0392-100X-N2223_ref70","doi-asserted-by":"crossref","unstructured":"Yang K, Li M, Zhu J, et al. Nomograms for predicting survival outcomes in intensity-modulated radiotherapy era of nasopharyngeal carcinoma: a study based on Epstein-Barr virus DNA biological responses. Head Neck 2021;43:1838-1847. https:\/\/doi.org\/10.1002\/hed.26654","DOI":"10.1002\/hed.26654"},{"key":"10.14639\/0392-100X-N2223_ref71","doi-asserted-by":"crossref","unstructured":"He SS, Wang CT, Peng ZW, et al. Development and external validation of a nomogram for predicting the overall survival of patients with stage II nasopharyngeal carcinoma after curative treatment. Cancer Manag Res 2019;11:4403-4412. https:\/\/doi.org\/10.2147\/CMAR.S202151","DOI":"10.2147\/CMAR.S202151"},{"key":"10.14639\/0392-100X-N2223_ref72","doi-asserted-by":"crossref","unstructured":"Siti-Azrin AH, Norsa\u2019adah B, Naing NN. Prognostic factors of nasopharyngeal carcinoma patients in a tertiary referral hospital: a retrospective cohort study. BMC Res Notes 2017;10:705. https:\/\/doi.org\/10.1186\/s13104-017-2990-1","DOI":"10.1186\/s13104-017-2990-1"},{"key":"10.14639\/0392-100X-N2223_ref73","doi-asserted-by":"crossref","unstructured":"Jiang Y, Qu S, Pan X, et al. Prognostic nomogram for locoregionally advanced nasopharyngeal carcinoma. Sci Rep 2020;10:861. https:\/\/doi.org\/10.1038\/s41598-020-57968-x","DOI":"10.1038\/s41598-020-57968-x"},{"key":"10.14639\/0392-100X-N2223_ref74","doi-asserted-by":"crossref","unstructured":"OuYang PY, Zhang LN, Lan XW, et al. The significant survival advantage of female sex in nasopharyngeal carcinoma: a propensity-matched analysis. Br J Cancer 2015;112:1554-1561. https:\/\/doi.org\/10.1038\/bjc.2015.70","DOI":"10.1038\/bjc.2015.70"},{"key":"10.14639\/0392-100X-N2223_ref75","doi-asserted-by":"crossref","unstructured":"Zhang Y, Yi JL, Huang XD, et al. Inherently poor survival of elderly patients with nasopharyngeal carcinoma. Head Neck 2015;37:771-776. https:\/\/doi.org\/10.1002\/hed.23497","DOI":"10.1002\/hed.23497"},{"key":"10.14639\/0392-100X-N2223_ref76","doi-asserted-by":"crossref","unstructured":"Stepan KO, Mazul AL, Skillington SA, et al. The prognostic significance of race in nasopharyngeal carcinoma by histological subtype. Head Neck 2021;43:1797-1811. https:\/\/doi.org\/10.1002\/hed.26639","DOI":"10.1002\/hed.26639"},{"key":"10.14639\/0392-100X-N2223_ref77","doi-asserted-by":"crossref","unstructured":"Wu SG, Lian CL, Wang J, et al. The effect of histological subtypes on survival outcome in nasopharyngeal carcinoma after extensive follow-up. Ann Transl Med 2019;7:768. https:\/\/doi.org\/10.21037\/atm.2019.11.75","DOI":"10.21037\/atm.2019.11.75"},{"key":"10.14639\/0392-100X-N2223_ref78","doi-asserted-by":"crossref","unstructured":"Lee JT, Ko CY. Has survival improved for nasopharyngeal carcinoma in the United States? Otolaryngol Head Neck Surg 2005;132:303-308. https:\/\/doi.org\/10.1016\/j.otohns.2004.09.018","DOI":"10.1016\/j.otohns.2004.09.018"},{"key":"10.14639\/0392-100X-N2223_ref79","doi-asserted-by":"crossref","unstructured":"Colaco RJ, Betts G, Donne A, et al. Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Clin Oncol (R Coll Radiol) 2013;25:171-177. https:\/\/doi.org\/10.1016\/j.clon.2012.10.006","DOI":"10.1016\/j.clon.2012.10.006"},{"key":"10.14639\/0392-100X-N2223_ref80","doi-asserted-by":"crossref","unstructured":"Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545. https:\/\/doi.org\/10.1016\/S0140-6736(00)04046-0","DOI":"10.1016\/S0140-6736(00)04046-0"},{"key":"10.14639\/0392-100X-N2223_ref81","doi-asserted-by":"crossref","unstructured":"Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008;454:436-444. https:\/\/doi.org\/10.1038\/nature07205","DOI":"10.1038\/nature07205"},{"key":"10.14639\/0392-100X-N2223_ref82","doi-asserted-by":"crossref","unstructured":"Lin W, Cao D, Dong A, et al. Systematic construction and external validation of an immune-related prognostic model for nasopharyngeal carcinoma. Head Neck 2022;44:1086-1098. https:\/\/doi.org\/10.1002\/hed.26996","DOI":"10.1002\/hed.26996"},{"key":"10.14639\/0392-100X-N2223_ref83","doi-asserted-by":"crossref","unstructured":"Yang S, Zhao K, Ding X, et al. Prognostic significance of hematological markers for patients with nasopharyngeal carcinoma: a meta-analysis. J Cancer 2019;10:2568-2577. https:\/\/doi.org\/10.7150\/jca.26770","DOI":"10.7150\/jca.26770"},{"key":"10.14639\/0392-100X-N2223_ref84","doi-asserted-by":"crossref","unstructured":"Takenaka Y, Kitamura T, Oya R, et al. Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: a meta-analysis. PLoS One 2017;12:E0181478. https:\/\/doi.org\/10.1371\/journal.pone.0181478","DOI":"10.1371\/journal.pone.0181478"},{"key":"10.14639\/0392-100X-N2223_ref85","doi-asserted-by":"crossref","unstructured":"Zeng X, Liu G, Pan Y, et al. Development and validation of immune inflammation-based index for predicting the clinical outcome in patients with nasopharyngeal carcinoma. J Cell Mol Med 2020;24:8326-8349. https:\/\/doi.org\/10.1111\/jcmm.15097","DOI":"10.1111\/jcmm.15097"},{"key":"10.14639\/0392-100X-N2223_ref86","doi-asserted-by":"crossref","unstructured":"Jin YN, Liu BQ, Peng KW, et al. The prognostic value of adding systemic inflammation response index to Epstein-Barr virus DNA in childhood nasopharyngeal carcinoma: a real-world study. Head Neck 2022;44:1404-1413. https:\/\/doi.org\/10.1002\/hed.27033","DOI":"10.1002\/hed.27033"},{"key":"10.14639\/0392-100X-N2223_ref87","doi-asserted-by":"crossref","unstructured":"Chen Y, Jiang W, Xi D, et al. Development and validation of nomogram based on SIRI for predicting the clinical outcome in patients with nasopharyngeal carcinomas. J Investig Med 2019;67:691-698. https:\/\/doi.org\/10.1136\/jim-2018-000801","DOI":"10.1136\/jim-2018-000801"},{"key":"10.14639\/0392-100X-N2223_ref88","doi-asserted-by":"crossref","unstructured":"Dickson RI. Nasopharyngeal carcinoma: an evaluation of 209 patients. Laryngoscope 1981;91:333-354. https:\/\/doi.org\/10.1288\/00005537-198103000-00001","DOI":"10.1288\/00005537-198103000-00001"},{"key":"10.14639\/0392-100X-N2223_ref89","doi-asserted-by":"crossref","unstructured":"Cai WM, Zhang HX, Hu YH, et al. Influence of biopsy on the prognosis of nasopharyngeal carcinoma \u2013 a critical study of biopsy from the nasopharynx and cervical lymph node of 649 patients. Int J Radiat Oncol Biol Phys 1983;9:1439-1444. https:\/\/doi.org\/10.1016\/0360-3016(83)90315-2","DOI":"10.1016\/0360-3016(83)90315-2"},{"key":"10.14639\/0392-100X-N2223_ref90","doi-asserted-by":"crossref","unstructured":"Li W, Lu H, Wang H, et al. Establishment and validation of a novel nomogram to predict overall survival in nasopharyngeal carcinoma with lymph node metastasis. Head Neck 2021;43:2353-2363. https:\/\/doi.org\/10.1002\/hed.26687","DOI":"10.1002\/hed.26687"},{"key":"10.14639\/0392-100X-N2223_ref91","doi-asserted-by":"crossref","unstructured":"Lv JW, Zhou GQ, Chen YP, et al. Refining the role of lymph node biopsy in survival for patients with nasopharyngeal carcinoma: population-based study from the surveillance epidemiology and end-results registry. Ann Surg Oncol 2017;24:2580-2587. https:\/\/doi.org\/10.1245\/s10434-017-5966-4","DOI":"10.1245\/s10434-017-5966-4"},{"key":"10.14639\/0392-100X-N2223_ref92","doi-asserted-by":"crossref","unstructured":"Yang XL, Wang Y, Bao Y, et al. Additional cervical lymph node biopsy is not a significant prognostic factor for nasopharyngeal carcinoma in the intensity-modulated radiation therapy era: a propensity score-matched analysis from an epidemic area. J Cancer 2018;9:2844-2851. https:\/\/doi.org\/10.7150\/jca.25505","DOI":"10.7150\/jca.25505"},{"key":"10.14639\/0392-100X-N2223_ref93","doi-asserted-by":"crossref","unstructured":"Chan AT, Gr\u00e9goire V, Lefebvre JL, et al. EHNS-ESMO-ESTRO Guidelines Working Group. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 (Suppl. 5):V187-V189. https:\/\/doi.org\/10.1093\/annonc\/mdq186","DOI":"10.1093\/annonc\/mdq186"},{"key":"10.14639\/0392-100X-N2223_ref94","doi-asserted-by":"crossref","unstructured":"Chen YP, Mao YP, Zhang et al. Prognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensity matched analysis. Oncotarget 2016;7:14973-14982. https:\/\/doi.org\/10.18632\/oncotarget.7789","DOI":"10.18632\/oncotarget.7789"},{"key":"10.14639\/0392-100X-N2223_ref95","doi-asserted-by":"crossref","unstructured":"Eskander A, Merdad M, Irish JC, et al. Volume-outcome associations in head and neck cancer treatment: a systematic review and meta-analysis. Head Neck 2014;36:1820-1834. https:\/\/doi.org\/10.1002\/ hed.23498","DOI":"10.1002\/hed.23498"},{"key":"10.14639\/0392-100X-N2223_ref96","doi-asserted-by":"crossref","unstructured":"Lee CC, Huang TT, Lee MS, et al. Survival rate in nasopharyngeal carcinoma improved by high caseload volume: a nationwide population-based study in Taiwan. Radiat Oncol 2011;6:92. https:\/\/doi.org\/10.1186\/1748-717X-6-92","DOI":"10.1186\/1748-717X-6-92"},{"key":"10.14639\/0392-100X-N2223_ref97","doi-asserted-by":"crossref","unstructured":"Goshtasbi K, Abiri A, Lehrich BM, et al. The influence of facility volume on patient treatments and survival outcomes in nasopharyngeal carcinoma. Head Neck 2021;43:2755-2763. https:\/\/doi.org\/10.1002\/hed.26739","DOI":"10.1002\/hed.26739"},{"key":"10.14639\/0392-100X-N2223_ref98","doi-asserted-by":"crossref","unstructured":"Yoshida EJ, Luu M, David JM, et al. Facility volume and survival in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2018;100:408-417. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.09.038","DOI":"10.1016\/j.ijrobp.2017.09.038"}],"container-title":["Acta Otorhinolaryngologica Italica"],"original-title":[],"link":[{"URL":"https:\/\/www.actaitalica.it\/article\/view\/2223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T07:21:13Z","timestamp":1729668073000},"score":1,"resource":{"primary":{"URL":"https:\/\/old.actaitalica.it\/article\/view\/2223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":98,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.14639\/0392-100x-n2223","relation":{},"ISSN":["1827-675X"],"issn-type":[{"value":"1827-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"article-number":"1"}}